The Pharmaceutical Division of SMC Enterprise Ltd started its journey in August 2017 with the key objective of “No one should suffer, especially the less-privileged due to lack of affordable quality medicine.” The goal of SMC’s pharmaceutical business is providing quality medicine for all segments of the population including those with limited income. It promotes 22 products in the market which includes antibiotic, anti-ulcerant, NSAIDs, anti-histamine, anti-asthmatic, anti-spasmodic and mineral supplement. These drugs belong to both the OTC category as well as the selective therapeutic class.

In November 2018, SMC Pharmaceutical Division has launched the first biological product –Aziday tablet (Azithromycin 500 mg). This drug is prescribed for the treatment of community-acquired pneumonia, pharyngitis, tonsillitis, acute otitis media, chronic obstructive pulmonary disease and uncomplicated skin and skin structure infection.

Our Pharma Division is moving forward with the philosophy “Profit must primarily contribute to social betterment.”